A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC)
for Muscle-invasive Urothelial Carcinoma
Drug: Nivolumab
26 locations incl. Springdale
Sponsor: Hoffmann-La Roche
Sex: All·Age: 18+
Code: NCT06534983·Phase 2·Recruiting